A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

NCT ID: NCT02433093

Last Updated: 2016-11-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-04-30
• Study Completion Date: 2015-09-30

Brief Summary

The study will assess the safety, tolerability, and pharmacokinetics of basimglurant compared to placebo after multiple ascending oral doses for up to 22 days in healthy subjects and in patients with MDD on stable selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) background therapy.

Conditions

Major Depressive Disorder, Healthy Volunteer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: DOUBLE

Study Groups

Basimglurant: Healthy Cohort (1)

Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. Cohort 1 will receive a prespecified titration scheme; however, adaptive titration schemes may be applied in subsequent cohorts.

Group Type: EXPERIMENTAL

Basimglurant

Intervention Type: DRUG

Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.

Basimglurant: Healthy Cohort (2)

Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 2 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in Cohort 1.

Group Type: EXPERIMENTAL

Basimglurant

Intervention Type: DRUG

Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.

Basimglurant: Healthy Cohort (3)

Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 3 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1 and 2.

Group Type: EXPERIMENTAL

Basimglurant

Intervention Type: DRUG

Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.

Basimglurant: Healthy Cohort (4)

Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 4 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1, 2, and 3.

Group Type: EXPERIMENTAL

Basimglurant

Intervention Type: DRUG

Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.

Basimglurant: MDD Cohort (5)

Participants with MDD assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 5 may differ from those previously evaluated; however, the titration steps and the highest dose tested will remain equal to or lower than the doses tested in Cohorts 1 to 4.

Group Type: EXPERIMENTAL

Basimglurant

Intervention Type: DRUG

Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.

Placebo: Healthy Cohorts (1 to 4)

Healthy participants will receive a 22-day regimen of matching placebo capsules.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Participants will receive 22 days of once-daily oral matching placebo capsules.

Placebo: MDD Cohort (5)

Participants with MDD will receive a 22-day regimen of matching placebo capsules.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Participants will receive 22 days of once-daily oral matching placebo capsules.

Interventions

Basimglurant

Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.

Intervention Type: DRUG

Placebo

Participants will receive 22 days of once-daily oral matching placebo capsules.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 18 to 65 years of age, inclusive
• Body weight at least 50 kg
• Healthy male or female subjects (Healthy Cohorts)
• Body mass index (BMI) 18 to 30 kg/m^2, inclusive (Healthy Cohorts)
• Nonsmoker for at least 90 days prior to dosing (Healthy Cohorts)
• Primary diagnosis of MDD without psychotic features (MDD Cohort)
• BMI 18 to 35 kg/m^2, inclusive (MDD Cohort)
• Current partial response to ongoing SSRI or SNRI antidepressant treatment at an adequate dose and for at least 4 weeks (MDD Cohort)
• Clinical Global Impression of Severity (CGI-S) score 3 or greater (MDD Cohort)
• Other regimens stable for at least 8 weeks prior to screening (MDD Cohort)

Exclusion Criteria

• Pregnant or lactating women
• History of alcohol or substance abuse in the past 6 months
• Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
• Clinically relevant electrocardiogram (ECG) abnormalities or a personal or family history of congenital long QT syndrome
• Participation in an investigational study within 90 days of screening
• Blood donation over 500 mL within 3 months of screening
• Hypersensitivity to any study medication or excipients
• Psychotic symptoms or comorbid mood disorder
• Significant suicide risk
• Major illness within 1 month before screening, or febrile illness within 1 week (Healthy Cohorts)
• Average alcohol consumption of more than 2 units per day (Healthy Cohorts)
• Multi-drug therapy for depression including antidepressants or adjunctive medications (MDD Cohort)
• Prior use of basimglurant (MDD Cohort)
• Cigarette use of greater than 1 pack per day (MDD Cohort)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Hoffmann-La Roche

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Garden Grove, California, United States

Countries

United States

Other Identifiers

NP29583

Identifier Type: -

Identifier Source: org_study_id